Bulbospinal Muscular Atrophy Drugs Market 2019 Increasing Healthcare Expenditure With Leadiant Biosciences, Inc, Abbott, Novo Nordisk A/S, AstraZeneca

Global Bulbospinal Muscular Atrophy Drugs Market research report consists of the systematic and comprehensive market research study that provides the facts and figures in the field of marketing. The report provides the market potential for each geographical region based on the growth rate, macroeconomic parameters, consumer buying patterns, their preferences for a particular product and market demand and supply scenarios. For sound decision making and superior management of goods and services, these days businesses are adopting a market research report solution. This report has well interpreted and well-categorized market research data that brings the marketplace clearly into the focus.

The global bulbospinal muscular atrophy drugs market is growing at a steady CAGR in the forecast period of 2019-2026. The report contains data of the base year 2018 and historic year 2017. This rise in market value can be attributed to the granting of various drug designations to novel drugs by the U.S FDA, initiatives are undertaken by various public, as well as nonprofit, organizations for creating awareness regarding bulbospinal muscular atrophy and increase in R&D investment by major companies.

Get Exclusive Sample PDF of Report at https://www.databridgemarketresearch.com/request-a-sample/?dbmr=global-bulbospinal-muscular-atrophy-drugs-market

The key market players in the global bulbospinal muscular atrophy drugs market are

Novartis AG,
F. Hoffmann-La Roche Ltd,
Boehringer Ingelheim International GmbH,
Pfizer Inc,
Ionis Pharmaceuticals, Inc,
CYTOKINETICS, INC,
Regeneron Pharmaceuticals, Inc,
Salarius Pharmaceuticals, Inc,
Leadiant Biosciences, Inc,
Abbott,
Novo Nordisk A/S,
Takeda Pharmaceutical Company Limited,
AstraZeneca,
Catalyst Pharma,
PTC Therapeutics,
Natera, Inc among others

Global Bulbospinal Muscular Atrophy Drugs Market By Drugs Class (5α-Reductase Inhibitors (5-ARIs), Gonadotropin-releasing Hormone (GnRH) Agonists and Others), Drugs (Leuprorelin, Dutasteride and Others), Therapy (Physical Therapy, Occupational Therapy, and Speech Therapy), Treatment (Medication, Supportive Care and Surgery), Route of Administration (Oral and Parenteral), Distribution Channel (Hospital Pharmacy, Retail Pharmacy and Online Pharmacy), End-Users (Hospitals, Homecare, Specialty Clinics and Others), Geography (North America, Europe, Asia-Pacific, South America, Middle East and Africa) - Industry Trends and Forecast to 2026

Market Definition:

Bulbospinal muscular atrophy is also known as Kennedy’s disease, a rare adult-onset form of spinal muscular atrophy (SMA) is an X-linked autosomal recessive progressive neurodegenerative disorder that causes weakening and wasting of the proximal and bulbar muscles. The condition occurs due to loss of nerve cells in the brain stem and spinal cord, this result in stoppage of messages from brain to muscles for movement. Patients with bulbospinal muscular atrophy have difficulty in speaking, standing, walking and controlling their head movements. In worse condition patients can have trouble swallowing and breathing. This disorder mainly affects men and does not occur in females, who are protected by their low levels of testosterone in the body, accounting for the sex-limited inheritance pattern of this disorder.

According to National Organization for Rare Disorders, Bulbospinal muscular atrophy or Kennedy disease is a very rare type of disorder and it affects 1 in 350,000 males and rarely seen in females. The Japanese population has a very high prevalence of this disorder because of a founder effect.

Market Drivers

Growing number of incidences of spinal bulbar muscular atrophy is driving the growth of the market

Initiatives undertaken by various public, as well as nonprofit, organizations for creating awareness regarding bulbospinal muscular atrophy also acts as a market driver

Increase in R&D investment by major companies is boosting the market growth
Increasing healthcare expenditure can also enhance the market growth

Market Restraints

High cost of treatment for bulbospinal muscular atrophy is hindering the market growth

Lack of experienced professionals in this field can also act as a restricting factor for the growth of this market

Limited number of drugs available for bulbospinal muscular atrophy treatment also hampers the market growth

Order a Copy of Global Bulbospinal Muscular Atrophy Drugs Market Report at https://www.databridgemarketresearch.com/inquire-before-buying/?dbmr=global-bulbospinal-muscular-atrophy-drugs-market

Segmentation: Global Bulbospinal Muscular Atrophy Drugs Market

By Drugs Class

5α-Reductase Inhibitors (5-ARIs)
Gonadotropin-releasing Hormone (GnRH) Agonists
Others

By Drugs

Leuprorelin
Dutasteride
Others

By Therapy

Physical Therapy
Occupational Therapy
Speech Therapy

By Treatment

Medication
Supportive Care
Surgery

By Route of Administration

Oral
Parenteral

By Distribution Channel

Hospital Pharmacy
Retail Pharmacy
Online Pharmacy

By End-Users

Hospitals
Homecare
Specialty Clinics

By Geography

North America
Europe
Asia-Pacific
South America
Middle East & Africa

Key Developments in the Market

In April 2019, Novartis AG is developing BVS857, a novel drug for the treatment of bulbospinal muscular atrophy, currently ongoing in phase ll clinical trial. If approved this novel drug will provide a potential treatment for patients with bulbospinal muscular atrophy and help in improving their life

In August 2018, Takeda Pharmaceutical Company Limited is developing Leuprorelin, a gonadotropin-releasing hormone (GnRH) agonist for the treatment of bulbospinal muscular atrophy. If approved this drug will provide a potential treatment for patients with bulbospinal muscular atrophy

Competitive Analysis:

Global bulbospinal muscular atrophy drugs market is highly fragmented and the major players have used various strategies such as new product launches, expansions, agreements, joint ventures, partnerships, acquisitions, and others to increase their footprints in this market. The report includes market shares of bulbospinal muscular atrophy drugs market for Global, Europe, North America, Asia-Pacific, South America and Middle East & Africa.

Reasons to Purchase this Report:

Current and future of global bulbospinal muscular atrophy drugs market outlook in the developed and emerging markets.

The segment that is expected to dominate the market as well as the segment which holds highest CAGR in the forecast period.

Regions/Countries that are expected to witness the fastest growth rates during the forecast period.

The latest developments, market shares, and strategies that are employed by the major market players.

Table of Contents:

1. Introduction
2. Market Segmentation
3. Market Overview
4. Executive Summary
5. Premium Insights
6. Global, By Component
7. Product Type
8. Delivery
9. Industry Type
10. Geography
10.1. Overview
10.2. North America
10.3. Europe
10.4. Asia-Pacific
10.5. South America
10.6. Middle East & Africa
11. Company Landscape
12. Company Profiles
13. Related Reports

Access Detailed TOC at https://www.databridgemarketresearch.com/toc/?dbmr=global-bulbospinal-muscular-atrophy-drugs-market

Contact:

Data Bridge Market Research
US: +1 888 387 2818
UK: +44 208 089 1725
Hong Kong: +852 8192 7475
Email: Corporatesales@databridgemarketresearch.com

About Data Bridge Market Research

An absolute way to forecast what future holds is to comprehend the trend today!

Data Bridge set forth itself as an unconventional and neoteric Market research and consulting firm with an unparalleled level of resilience and integrated approaches. We are determined to unearth the best market opportunities and foster efficient information for your business to thrive in the market. Data Bridge endeavors to provide appropriate solutions to complex business challenges and initiates an effortless decision-making process. Data Bridge is an aftermath of sheer wisdom and experience which was formulated and framed in the year 2015 in Pune.

This release was published on openPR.